Skip to main content

Antibe Therapeutics Inc(ATE-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.70
Day High0.71
Open:0.71
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: Antibe Therapeutics Inc.
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Monday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Friday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Thursday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Tuesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Monday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Friday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Thursday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Wednesday (ATE)
Baystreet
Stocks in play: Antibe Therapeutics Inc
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Monday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc flat on Friday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Thursday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Friday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Friday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc flat on Thursday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Monday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Friday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Thursday (ATE)
Baystreet
Stocks in play: Antibe Therapeutics Inc.
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc up on Monday (ATE)
AI-generated - The Globe and Mail
Closing Bell: Antibe Therapeutics Inc down on Friday (ATE)

Profile

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.